Canaccord Genuity Group Issues Positive Forecast for Establishment Labs (NASDAQ:ESTA) Stock Price

Establishment Labs (NASDAQ:ESTA) had its target price increased by Canaccord Genuity Group from $85.00 to $90.00 in a report published on Thursday morning,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

Several other analysts have also recently issued reports on ESTA. Mizuho increased their target price on Establishment Labs from $90.00 to $100.00 and gave the company an “outperform” rating in a research report on Wednesday. JPMorgan Chase & Co. upped their price objective on Establishment Labs from $71.00 to $80.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. Stephens raised their price objective on Establishment Labs from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Wednesday. BTIG Research boosted their target price on shares of Establishment Labs from $86.00 to $88.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research report on Monday, December 29th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $87.00.

Establishment Labs Stock Down 1.5%

NASDAQ:ESTA opened at $77.15 on Thursday. The company has a debt-to-equity ratio of 15.06, a current ratio of 3.33 and a quick ratio of 2.10. Establishment Labs has a 1-year low of $26.56 and a 1-year high of $83.31. The company has a 50-day moving average of $71.21 and a 200 day moving average of $58.00. The firm has a market cap of $2.24 billion, a PE ratio of -44.34 and a beta of 0.99.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.13. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 197.22%. The business had revenue of $64.62 million during the quarter, compared to analyst estimates of $63.80 million. During the same quarter in the previous year, the business posted ($1.19) EPS. The company’s quarterly revenue was up 45.2% compared to the same quarter last year. As a group, research analysts anticipate that Establishment Labs will post -2.41 EPS for the current fiscal year.

Institutional Investors Weigh In On Establishment Labs

A number of large investors have recently bought and sold shares of ESTA. Quarry LP acquired a new position in Establishment Labs in the 3rd quarter worth approximately $34,000. Kestra Advisory Services LLC purchased a new stake in shares of Establishment Labs in the 4th quarter valued at $47,000. State of Wyoming acquired a new stake in shares of Establishment Labs in the third quarter worth $71,000. Osaic Holdings Inc. raised its holdings in shares of Establishment Labs by 900.0% during the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after purchasing an additional 1,800 shares during the last quarter. Finally, CWM LLC raised its holdings in shares of Establishment Labs by 45.9% during the second quarter. CWM LLC now owns 2,182 shares of the company’s stock worth $93,000 after purchasing an additional 686 shares during the last quarter. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Establishment Labs News Summary

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: Multiple brokerages raised price targets and kept bullish ratings — Canaccord raised its target to $90 and kept a Buy rating, Stephens raised to $90 with an Overweight, Mizuho lifted to $100 with an Outperform, and BTIG moved to $88 with a Buy — reinforcing analyst conviction and upside. Analyst Price Target Raises (Benzinga)
• Positive Sentiment: Q4 2025 results beat expectations: revenue (~$64.6M) and EPS beat consensus, with year‑over‑year revenue growth (~45%) — results and commentary underpin the recent analyst upgrades. Q4 2025 Earnings Call Summary (Yahoo)
• Positive Sentiment: Management provided 2026 guidance targeting at least 25% revenue growth and emphasized expansion of minimally invasive platforms — a clear growth thesis that supports higher valuation if execution continues. 2026 Revenue Guidance & Platform Expansion (MSN)
• Neutral Sentiment: Company announced a leadership transition framed as supporting the next phase of growth — this is management-level news to monitor for execution risk but not an immediate negative. Leadership Transition (Yahoo)
• Neutral Sentiment: Analyst note roundup summarizes 11 analysts’ views — useful context on street sentiment and target dispersion but adds no single new catalyst. Analyst Roundup: 11 Analysts (Benzinga)
• Negative Sentiment: Market reaction: shares are trading lower today despite the earnings beat, guidance and several price‑target raises — suggests some profit‑taking or skepticism about margins/near‑term profitability. Market Reaction

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.